These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

261 related items for PubMed ID: 9819223

  • 1. Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor.
    Zhai X, Beckmann H, Jantzen HM, Essigmann JM.
    Biochemistry; 1998 Nov 17; 37(46):16307-15. PubMed ID: 9819223
    [Abstract] [Full Text] [Related]

  • 2. Human testis-determining factor SRY binds to the major DNA adduct of cisplatin and a putative target sequence with comparable affinities.
    Trimmer EE, Zamble DB, Lippard SJ, Essigmann JM.
    Biochemistry; 1998 Jan 06; 37(1):352-62. PubMed ID: 9425057
    [Abstract] [Full Text] [Related]

  • 3. Cisplatin-DNA adducts are molecular decoys for the ribosomal RNA transcription factor hUBF (human upstream binding factor).
    Treiber DK, Zhai X, Jantzen HM, Essigmann JM.
    Proc Natl Acad Sci U S A; 1994 Jun 07; 91(12):5672-6. PubMed ID: 8202546
    [Abstract] [Full Text] [Related]

  • 4. Binding of tsHMG, a mouse testis-specific HMG-domain protein, to cisplatin-DNA adducts.
    Ohndorf UM, Whitehead JP, Raju NL, Lippard SJ.
    Biochemistry; 1997 Dec 02; 36(48):14807-15. PubMed ID: 9398202
    [Abstract] [Full Text] [Related]

  • 5. Basis for recognition of cisplatin-modified DNA by high-mobility-group proteins.
    Ohndorf UM, Rould MA, He Q, Pabo CO, Lippard SJ.
    Nature; 1999 Jun 17; 399(6737):708-12. PubMed ID: 10385126
    [Abstract] [Full Text] [Related]

  • 6. Binding of Ixr1, a yeast HMG-domain protein, to cisplatin-DNA adducts in vitro and in vivo.
    McA'Nulty MM, Whitehead JP, Lippard SJ.
    Biochemistry; 1996 May 14; 35(19):6089-99. PubMed ID: 8634251
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin.
    Takahara PM, Rosenzweig AC, Frederick CA, Lippard SJ.
    Nature; 1995 Oct 19; 377(6550):649-52. PubMed ID: 7566180
    [Abstract] [Full Text] [Related]

  • 12. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
    Roberts JJ, Friedlos F.
    Cancer Res; 1987 Jan 01; 47(1):31-6. PubMed ID: 3791217
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. DNA binding mode of the cis and trans geometries of new antitumor nonclassical platinum complexes containing piperidine, piperazine, or 4-picoline ligand in cell-free media. Relations to their activity in cancer cell lines.
    Kasparkova J, Marini V, Najajreh Y, Gibson D, Brabec V.
    Biochemistry; 2003 May 27; 42(20):6321-32. PubMed ID: 12755637
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of a piperidine ligand on DNA modification by antitumor cisplatin analogues.
    Kasparkova J, Novakova O, Najajreh Y, Gibson D, Perez JM, Brabec V.
    Chem Res Toxicol; 2003 Nov 27; 16(11):1424-32. PubMed ID: 14615968
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.